Report Categories
View AllRecent Articles
View All
Market Recap Tech leads sector gains while consumer names lag
What Nuveen NZF has done differently this quarter NZF Quarterly Earnings Nuveen Fund Reports Results Market Volatility Persists
Is Disc Medicine IRON building a durable competitive moat Buying Pressure 20260508
STRA Strategic Education Inc posts 207 percent Q4 2025 EPS beat shares rise 16 percent in todays trading
Market Recap Tech leads gains while consumer sector lags market
LPG Dorian LPG Ltd shares climb 295 percent on investor optimism despite Q1 2026 EPS miss
PAAS Pan American Silver Corp tops Q4 2025 EPS estimates and posts 28 percent year over year revenue growth yet shares drop 134 percent today
Why DT Midstream DTM deserves a spot on your radar now Smart Money Exits 20260508
The Vita Coco Company Inc COCO reports Q4 2025 285 EPS miss with negligible postearnings stock price reaction
Charter Communications CHTR Mixed Q4 2025 Earnings Results Amid Broader Telecom Sector SafeHaven Rally
NIO Inc NIO Poised for DoubleDigit Growth Amid Expanding NEV Market Tailwinds
Rubico RUBI Stock Protective Put Eye on Rally 20260420
ASBA Assoc Banc posts Q4 2025 EPS 131 percent above analyst estimates with its stock notching small gains today
MIND MIND Stock Fundamental Signals On the Radar 20260420
STRL Sterling Infrastructure delivers solid Q4 2025 performance tops EPS forecasts with 177 percent revenue growth
TGL Treasure Global reports far smaller Q3 2024 loss than analyst forecasts shares dip 162 percent in todays trading session
Waystar Holding WAY Stock Key Catalysts Ahead Slight Gain 20260420
NVIDIA Corporation NVDA 5 Trillion Market Cap Assessment Buy Sell or Hold
Moderna Inc MRNA Secures EU Marketing Authorization for COVID19Influenza Combo Vaccine Advances Pandemic Preparedness Pipeline
Market Wrap SP 500 dips slightly as major indices slide and mild volatility persists
External Links
OOMA Ooma Inc tops first quarter 2026 earnings per share estimates shares rise more than five percent
NBIS Nebius posts 462 percent Q4 2025 revenue growth and narrower than expected losses despite a minor postearnings stock dip
Is institutional money buying Galectin Therapeutics GALT stock Smart Money Exits 20260420